Presentation is loading. Please wait.

Presentation is loading. Please wait.

P-4E-BP1/4E-BP1P-p70 S6K/p70 S6K ND cleaved PARP/PARPLC3II/LC3I Supplementary Figure 1 Relative levels A BC P-Akt/Akt.

Published byHilary Shields Modified over 9 years ago

Similar presentations

Presentation on theme: "P-4E-BP1/4E-BP1P-p70 S6K/p70 S6K ND cleaved PARP/PARPLC3II/LC3I Supplementary Figure 1 Relative levels A BC P-Akt/Akt."— Presentation transcript:

1 P-4E-BP1/4E-BP1P-p70 S6K/p70 S6K ND cleaved PARP/PARPLC3II/LC3I Supplementary Figure 1 Relative levels A BC P-Akt/Akt

2 Supplementary Figure 2 B MTS reduction (% of control) Viability (% of control) Rapamycin (nM) Days C Cell number (x10 5 ) Jurkat hours SNT13KHYG1 hours KAI3 A * * * * * * * * * * * * * * * * * * * * * * * *

3 P-4E-BP1 P-p70 S6K SNT16 - + SNK6 - + CCI-779 p27 CDK2 Rb Supplementary Figure 3 A B C β-Actin %of total * * * * ** * *

4 Supplementary Figure 4 Days * * * * * * * * * * * * * CCI-779 Tumor volume (mm 3 )

Download ppt "P-4E-BP1/4E-BP1P-p70 S6K/p70 S6K ND cleaved PARP/PARPLC3II/LC3I Supplementary Figure 1 Relative levels A BC P-Akt/Akt."

Similar presentations

Supplementary Figure 1: Co-treatment with SAHA and PLX4720 increases the level of a ~50kD fragment of PARP. Whole cell lysates from MM200 and Sk-Mel-28.

Supplementary Figure 1: Co-treatment with SAHA and PLX4720 increases the level of a ~50kD fragment of PARP. Whole cell lysates from MM200 and Sk-Mel-28.
Supplementary Data shLuc sh14-3-3   sh14-3-3  179 shLuc sh14-3-3   sh14-3-3  179 Asyn Noco 2.1% 6.1% 2.4% 16.5%11.4%1.1% 5.9%3.9%2.5% 52.5%10.0%4.9%

Supplementary Data shLuc sh   sh  179 shLuc sh   sh  179 Asyn Noco 2.1% 6.1% 2.4% 16.5%11.4%1.1% 5.9%3.9%2.5% 52.5%10.0%4.9%
Figure S1 A P

Figure S1 A P
P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.
Herceptin + 17-AAG Combination BT-474 Tumors

Herceptin + 17-AAG Combination BT-474 Tumors
BEL7402Huh7 C Tet Rapa C Tet Rapa LC3-II LC3-I GAPDH Figure S1 Detecting Tetrandrine-induced autophagy in Huh7 and BEL7402 cell lines. Rapamycin treatment.

BEL7402Huh7 C Tet Rapa C Tet Rapa LC3-II LC3-I GAPDH Figure S1 Detecting Tetrandrine-induced autophagy in Huh7 and BEL7402 cell lines. Rapamycin treatment.
Supplementary Figures&Legends. Figure1. Subcutaneous xenograft tumor models of the control group.

Supplementary Figures&Legends. Figure1. Subcutaneous xenograft tumor models of the control group.
Supplementary Figure 1A-B A H1299 RH1299 0 15 30 45 60 0 45 80 160 200 LC3-I / II P-GSK-3 (Ser21/9) GSK-3α/β β-actin β-catenine P-GSK-3 (Tyr279/216) B.

Supplementary Figure 1A-B A H1299 RH LC3-I / II P-GSK-3 (Ser21/9) GSK-3α/β β-actin β-catenine P-GSK-3 (Tyr279/216) B.
Supplemental Table 1 Source and authentication of cell lines.

Supplemental Table 1 Source and authentication of cell lines.
Supplementary Data. β-actin IL-13Rα2 65 kDa 42 kDa G26-H2 G26-V2 SnB19-pcDNA SnB19-asIL-13Rα2 Figure S1A.

Supplementary Data. β-actin IL-13Rα2 65 kDa 42 kDa G26-H2 G26-V2 SnB19-pcDNA SnB19-asIL-13Rα2 Figure S1A.
Con WTTM Supplementary Figure 1 Supplementary Figure 1. Tumor histopathology of the lungs. (a) Histological examination of lungs of 52-week-old K- ras.

Con WTTM Supplementary Figure 1 Supplementary Figure 1. Tumor histopathology of the lungs. (a) Histological examination of lungs of 52-week-old K- ras.
A B Supplementary Figure 1. (A) Western blots were performed on the three cell lines to analyze the levels of p-ERK, which is a key protein involved in.

A B Supplementary Figure 1. (A) Western blots were performed on the three cell lines to analyze the levels of p-ERK, which is a key protein involved in.
Nardella et al. Supplementary Fig. 1 Murine Rheb 0 0.5 1 1.5 wt Line 47 Line 50 Log gene expression (a.u.) ******* 200 bp Founders 474849505152597086878889.

Nardella et al. Supplementary Fig. 1 Murine Rheb wt Line 47 Line 50 Log gene expression (a.u.) ******* 200 bp Founders
CDK Inhibitors: Cell Cycle Regulators and Beyond Arnaud Besson, Steven F. Dowdy, James M. Roberts Developmental Cell Volume 14, Issue 2, Pages 159-169.

CDK Inhibitors: Cell Cycle Regulators and Beyond Arnaud Besson, Steven F. Dowdy, James M. Roberts Developmental Cell Volume 14, Issue 2, Pages
Supplemental Figure 1.A. Frequency of CCND1 aberrations by tumor type. Included primary cancer diagnosis with N ≥ 20. See Supplemental Table 1 for complete.

Supplemental Figure 1.A. Frequency of CCND1 aberrations by tumor type. Included primary cancer diagnosis with N ≥ 20. See Supplemental Table 1 for complete.
Farmer et al Supplementary Figure 1 KU0058684 PARP-1 IC 50 = 3.2nM KU0058948 PARP-1 IC 50 = 3.4nM KU0051529 PARP-1 IC 50 = 730nM a b 0 0.001 0.01 0.1 1.

Farmer et al Supplementary Figure 1 KU PARP-1 IC 50 = 3.2nM KU PARP-1 IC 50 = 3.4nM KU PARP-1 IC 50 = 730nM a b
Condition MiaPaCa-2 Control Gem (100nm) AZD1775 (200nM) Gem + AZD1775 Panc-1 Control Gem (50nm) AZD1775 (200nM) Gem + AZD1775 Capan-1 Control Gem (50nm)

Condition MiaPaCa-2 Control Gem (100nm) AZD1775 (200nM) Gem + AZD1775 Panc-1 Control Gem (50nm) AZD1775 (200nM) Gem + AZD1775 Capan-1 Control Gem (50nm)
Differential drug responses of circulating tumor cells within patient blood Andrew D. Hughes, Jocelyn R. Marshall, Eric Keller, John D. Powderly, Bryan.

Differential drug responses of circulating tumor cells within patient blood Andrew D. Hughes, Jocelyn R. Marshall, Eric Keller, John D. Powderly, Bryan.
Figure1 HER2 SKBr3 PC3 A. SKBr3 cells Figure1 0 0.03 0.3 3 30 (µM) 120 100 80 60 40 20 0 Penetratin control % of control 0 0.03 0.3 3 30 (µM) 120 100.

Figure1 HER2 SKBr3 PC3 A. SKBr3 cells Figure (µM) Penetratin control % of control (µM)
ПЕЧЕНЬ 9. Закладка печени в период эмбрионального развития.

ПЕЧЕНЬ 9. Закладка печени в период эмбрионального развития.

Similar presentations

Ads by Google